HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
暂无分享，去创建一个
H. Gogas | R. Wirtz | G. Aravantinos | G. Fountzilas | G. Pentheroudakis | R. Kronenwett | D. Pectasides | A. Batistatou | G. Polychronidou | K. Kalogeras | A. Eleftheraki | E. Timotheadou | A. Koutras | V. Kotoula | C. Christodoulou | M. Bobos | D. Vlachodimitropoulos | C. Valavanis | N. Soupos | O. Tzaida | P. Arapantoni | Mattheos Bobos